Objectives-Postprandial
A pproximately 60% of patients reaching low-density lipoprotein (LDL) cholesterol (LDL-C) therapeutic goal under lipid-lowering therapy remain at high cardiovascular risk. 1 Such patients are often characterized by a low highdensity lipoprotein (HDL) cholesterol (HDL-C) phenotype and high circulating levels of triglyceride (TG)-rich lipoproteins (TRL). Designated as a broad spectrum lipid-lowering agent, niacin was the first therapy used to reduce total cholesterol, LDL-C, and TG and to increase HDL-C levels. 2 In this context, adding niacin to a background of statin therapy was a promising concept to reduce residual cardiovascular risk. However, 2 major clinical trials, The Atherothrombosis Intervention in Metabolic Syndrome with low HDL/high TG: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), failed to demonstrate the efficacy of niacin to further reduce occurrence of cardiovascular events in high cardiovascular-risk patients receiving a statin therapy. [3] [4] [5] Despite observational studies indicating an inverse relationship between HDL-C levels and cardiovascular risk, 6 recent outcome trials on cholesteryl ester transfer protein (CETP) inhibition 7 along with a study on human genetics 8 highlighted that raising simply HDL-C levels may not be sufficient to confer an efficacious cardioprotection, thus emerging the concept of HDL function. The ability of HDL to accept cholesterol from macrophages represents the early step of the reverse cholesterol transport (RCT). 9 It has been demonstrated that the capacity of HDL to mediate cholesterol efflux represents a strong predictor of the presence and the extend of atherosclerosis. 10 Equally, an inverse association between the prevalence of coronary disease and HDL efflux capacity has been observed; however, HDL-mediated efflux was paradoxically associated with increase in prospective risk of myocardial infarction, stroke, and death. 11 These observations suggest that it is important to consider the overall efficacy of RCT pathway, including not only macrophage cholesterol efflux, but also the return of cholesterol to the liver and the ultimate excretion of cholesterol from the body.
The efficacy of RCT pathway can be influenced by several factors. Postprandial lipemia, characterized by a transient production and accumulation of TRL, is associated with an acceleration of RCT. 12, 13 Indeed, it is important to consider that intravascular metabolism of both TRL and HDL is intimately intricate: (1) CETP-mediated neutral lipid heteroexchange between TRL and HDL induces the formation of cholesteryl ester (CE)-rich TRL remnants and TG-rich HDL particles and (2) the transfer of phospholipids and cholesterol from lipid surface of TRL to HDL allows formation of mature HDL particles.
14 In this context, it has been reported that patients displaying a low HDL phenotype are characterized by an exacerbated postprandial hypertriglyceridemia, 15 indicating that reduced HDL-C levels directly impact intravascular metabolism of TRL particles. In such patients, postprandial phase is associated with an increase in cholesterol efflux from macrophages as a result of CETP-mediated intravascular HDL remodeling and liberation of lipid poor/lipid free apolipoprotein (apo) AI. 16 However, enhanced CETP-mediated CE transfer from HDL to postprandial TRL induces formation and accumulation of CE-enriched lipoprotein remnants that represent preferential precursors of atherogenic small dense LDL particles, displaying a reduced affinity for the hepatic lowdensity lipoprotein receptor. 17 Equally, HDL particles generated during postprandial phase have been shown to display a reduced ability to deliver CE to the liver. 16 Taken together, these observations indicate that despite improvement of cholesterol efflux from macrophage, postprandial lipemia is associated with a global reduction of RCT efficacy because the ultimate return of cholesterol to the liver, directly or indirectly, is reduced in patients displaying a low HDL-C phenotype. Niacin has long been known to efficiently reduce the coexisting lipid triad consisting of TRL, TRL remnants, and small dense LDL particles in hyperlipidemic patients. 18 In addition, it has been reported that extended-release niacin (ERN) given in a single dose 1 hour before oral fat tolerance test significantly reduces postprandial TG levels in healthy volunteers. 19 The objective of the present study was to evaluate the impact of ERN/laropiprant (LRPT) on the overall efficacy of RCT pathway after ingestion of a typical western meal in dyslipidemic patients at high cardiovascular risk on a background of statin treatment. RCT pathway was evaluated through an integrated functional approach by measuring its major steps, including the initial macrophage cholesterol efflux, CETPmediated CE transfer from HDL to apoB-containing lipoprotein, and in vitro hepatic HDL-CE uptake, as well as in vivo HDL-mediated RCT to feces.
Materials and Methods
Detailed information is available in Materials and Methods in the online-only Data Supplement.
Results

Impact of ERN/LRPT Therapy on Fasting Plasma Lipid and Apolipoprotein Levels
Before initiation of ERN/LRPT therapy, dyslipidemic patients received statins (20-40 mg/d) during 4 weeks to stabilize their plasma lipid levels within the normal range (Table) . After administration of ERN/LRPT on background of statins during 12 weeks, significant reductions in plasma levels of TGs (−26%; P<0.02), total cholesterol (−12%; P<0.02), LDL-C (−21%; P<0.002), and apoB (−21%; P<0.001) were observed. Concomitantly, a significant elevation in HDL-C levels (+17%; P=0.02) were observed; however, those of both apoAI and apoAII were only slightly and not significantly modified by ERN/LRPT therapy. Note that the ERN/LRPTinduced changes in lipid parameters presently reported are entirely consistent with known effects of niacin or with those previously reported for ERN/LRPT in patients with dyslipidemia. 20 Interestingly, plasma levels of apoE were reduced by 19% (P<0.03) after ERN/LRPT, whereas those of apoCII and apoCIII were not significantly affected. Taken together, these observations indicate that even under stable statin therapy, administration of ERN/LRPT in dyslipidemic patients allow the establishment of an anti-atherogenic plasma lipid profile as shown by the reduction in total cholesterol to HDL-C ratio (−23%; P<0.01).
Impact of ERN/LRPT Therapy on Postprandial Lipoprotein Subspecies
Combination therapy with niacin-laropiprant significantly reduced postprandial hypertriglyceridemia after consumption of a typical solid mixed meal as shown by significant reduction of incremental area under the curve of TG (−53%; Figure 1A ). Such variations predominantly reflect postprandial changes in large TRL subspecies, that is, chylomicrons (incremental area under the curve-chylomicrons-TG: −53%;P<0.004; Figure 1B ) and very-low density lipoprotein-1 (VLDL-1; area under curve [AUC]-VLDL-1-TG: −44%;P<0.0001; Figure 1C ). Interestingly, ERN/LPRT treatment abolished the postprandial elevation of VLDL-1-TG levels. In addition, treatment with ERN/LRPT significantly reduced circulating levels of VLDL-2 particles; however, no significant postprandial variation in VLDL-2 levels was observed ( Figure 1C ). Taken together, our results revealed that ERN/LRPT reduces the magnitude of postprandial TRL levels. After ERN/LRPT therapy, we observed a reduction in AUC for plasma LDL-C levels (−16%; P<0.02, Figure IA in the online-only Data Supplement). By contrast, the AUC for plasma HDL-C levels was significantly increased by ERN/ LPRT therapy (+13%; P<0.05) as a result of a specific increment (+17%; P<0.05) in the AUC for large HDL2 subfraction ( Figure IB in the online-only Data Supplement). Analysis of individual HDL subspecies revealed that ERN/LRPT-induced elevation in postprandial plasma levels of HDL-C exclusively results from a specific increment in circulating levels of large HDL2b subfraction (+17%; P<0.05). Note that postprandial variations in circulating levels of both LDL-C and HDL-C are entirely consistent with those reported in earlier studies. [21] [22] [23] Independently of ERN/LRPT treatment, no significant impact of postprandial phase was observed on plasma levels of apoB, apoAI, and apoAII levels ( Figure IA and IB in the online-only Data Supplement).
Before ERN/LRPT treatment, postprandial phase was associated with a significant increment in circulating apoE levels, reaching a peak 4 hour after meal intake. Interestingly, such postprandial increase in apoE levels was abolished after ERN/LRPT treatment ( Figure 2A ). Equally, before ERN/ LRPT treatment, test meal consumption had no impact on apoCII levels, which remain constant throughout the postprandial phase. Interestingly, ERN/LRPT induced a significant postprandial elevation in plasma levels of apoCII ( Figure 2B ), which occurred concomitantly with a reduction in apoCIII levels ( Figure 2C ). Because apoCII and apoCIII, respectively, represent activator and inhibitor of lipoprotein lipase, these observations suggest that intravascular catabolism of TRL particles is accelerated after ERN/LRPT treatment.
Impact of ERN/LRPT on Key Steps of Reverse Cholesterol Transport Pathway During Postprandial Phase
We observed a significant impact of niacin-laropiprant on postprandial plasma cholesterol efflux capacity from human macrophages (−9.3%; P<0.04; Figure 3A ) and via ATP-binding cassette A1 (ABCA1) pathway (−8.5%; P<0.05; Figure 3B ). Interestingly, opposite variations were observed on scavenger receptor class B type 1 (SR-BI) and ATP-binding cassette G1 (ABCG1) pathways because ERN/LRPT induced a slight but significant increase in AUC of SR-BI-dependent plasma efflux capacity (+5.5%; P<0.05; Figure 3C ) and of ABCG1-dependent plasma efflux capacity (+5.2%; P<0.05; Figure 3D ). Efflux experiments have been equally performed using apoB-depleted plasma as cholesterol efflux acceptors ( Figure II in the onlineonly Data Supplement). ERN/LRPT treatment was without any significant effect on cholesterol efflux to apoB-depleted plasma evaluated on human THP-1 macrophages or on Chinese hamster ovary cells over expressing ABCA1. By contrast, SR-BIdependent cholesterol efflux to apoB-depleted plasma was significantly increased after ERN/LRPT therapy as a result of potentially niacin-induced elevation in circulating levels of large HDL particles. There was no significant impact of ERN/ LRPT on the capacity of isolated postprandial HDL subspecies to mediate cholesterol efflux either from human macrophages or through specific efflux pathway ( Figure III in the online-only Data Supplement). Taken together, our observations indicate that the increase in plasma cholesterol efflux capacity from human macrophages primarily involves the SR-BI pathway and is mainly related to an increase in the quantity of HDL with no modification of their intrinsic efflux capacity.
Before ERN/LRPT therapy, we observed that endogenous CETP activity increased significantly during postprandial state and peaked 6 hours after meal intake (+22%;P<0.0001). Remarkably, such postprandial increase was abolished after ERN/LRPT treatment ( Figure 3E ). These observations indicate that ERN/LRPT treatment significantly reduced postprandial endogenous CETP-dependent CE transfer from HDL to apoB-containing lipoproteins, including TRL particles (AUC for CETP, 12.6%; P<0.02 versus before ERN/ LRPT treatment). In addition, after ERN/LRPT treatment, we observed a significant reduction in plasma CETP concentrations (−15%; P<0.02). However, we did not observe any significant variation in plasma CETP levels throughout the postprandial phase as previously reported in studies using a test meal, including a similar amount of cholesterol. The impact of ERN/LRPT treatment on the capacity of postprandial HDL particles to deliver CE to hepatic cells was evaluated using HepG2 cells ( Figure 3F ). Before ERN/ LRPT therapy, we observed that HDL particles isolated 6 and 8 hours after meal intake displayed a significant reduction in their capacity to deliver CE to hepatic cells (−18%; P<0.03 and −17%; P<0.04, 6 and 8 hours, respectively) as compared with those isolated before meal intake. By contrast, after ERN/LRPT treatment, opposite postprandial changes were observed. Indeed, the capacity of postprandial HDL particles showed a progressive increase in their capacity to deliver CE to hepatic cells ≤8 hours postprandially (+26%; P<0.005) as compared with before meal intake. Taken together, these observations indicate that 6 and 8 hours after meal intake, HDL particles isolated from patients receiving ERN/LRPT displayed an enhanced capacity to deliver CE to hepatic cells as compared with their equivalent counterpart isolated from patients not receiving ERN/LRPT (+22.6%; P<0.009 and +39.3%; P<0.0005 at 6 and 8 hours, respectively).
Niacin Improves the Capacity of Postprandial HDL to Promote RCT to Feces In Vivo
Similar to our current observations in dyslipidemic patients, evaluation of ERN/LRPT impact on RCT efficiency in human ApoB/CETP double transgenic mice fed with chow diet supplemented with 1% niacin during an 8-week period showed significant reductions in plasma concentrations of total cholesterol (−36%; P<0.0005), triglycerides (−42%; P<0.02), and apoB (−44%%; P<0.03) when compared with ApoB/CETP double transgenic mice fed with chow diet (Figure 4A-4C) . Concomitantly, we observed a significant increase in HDL-C levels (+11%; P<0.05) in mice receiving niacin ( Figure 4D ). In addition, human ApoB/CETP double transgenic mice fed with chow diet supplemented with niacin displayed a significant reduction in plasma CETP activity (−30%; P<0.05; Figure 4E ) as well as in the capacity of plasma to stimulate cholesterol efflux from human THP-1 macrophages (−11%; P<0.05; Figure 4F ).
The capacity of postprandial HDL particles isolated from dyslipidemic patients before and after ERN/LRPT treatment to promote RCT to feces was evaluated in vivo in human ApoB/ CETP double transgenic mice fed ad libidum a normal chow diet supplemented with ( Figure 5A ) or without ( Figure 5B) 1% niacin during an 8-week period. After injection, plasma clearance of radioactivity was similar for labeled HDL particles isolated from both treated and untreated patients at 0 and 8 hours after meal intake. In vivo liver uptake of radioactive tracer derived from postprandial HDL particles from untreated patients was significantly reduced (P<0.05) as compared with HDL particles isolated before meal intake. By contrast, after ERN/LPRT treatment, we observed an increased (P<0.05) in vivo liver uptake of postprandial HDL particles as compared with HDL particles isolated before meal intake. Similarly, quantification of radioactivity excreted into feces revealed that postprandial HDL particles isolated from patients before ERN/LRPT treatment displayed a significant reduced capacity (P<0.05) for HDL-mediated RCT to feces. By contrast, the capacity of postprandial HDL isolated after ERN/LRPT treatment for HDL-mediated RCT to feces was enhanced or at least maintained, resulting in a significant 2-fold (P<0.0003) increase in the capacity of postprandial HDL particles for HDL-mediated RCT to feces as compared with their counterpart isolated before ERN/LPRT treatment.
To identify potential mechanism underlying the impact of niacin on RCT pathway efficacy, we evaluated both liver and intestine expression of various genes involved in lipid metabolism. We presently observed that niacin consumption reduced intestine expression of P2Y13 (−26%; P<0.001) and ACAT2 (−58%; P<0.001) and increased those of ABCA1 (+74%; P<0.003) in human ApoB/CETP double transgenic mice ( Figure 6A ). Equally, niacin consumption reduced liver expression of human CETP gene (−37%; P=0.005), P2Y13 (−26%; P<0.02), and ABCG1 (−37%; P<0.002) in human ApoB/CETP double transgenic mice model ( Figure 6B ).
Discussion
Here, we report that in patients at high cardiovascular risk under current statin therapy, ERN/LRPT efficiently attenuates atherogenic postprandial hypertriglyceridemia by decreasing circulating levels of TRL and improves overall RCT efficacy, thus favoring cholesterol elimination from the body.
Herein, we observed that dyslipidemic patients treated with statins displayed an exaggerated postprandial response after meal intake. ERN/LRPT reduced such postprandial hypertriglyceridemic response by almost 50%, showing an additional beneficial effect of niacin over statin treatment. This observation is in good accordance with a previous study showing that ERN lowered postprandial triglyceridemia in normolipidemic healthy volunteers. 19 By limiting postprandial hypertriglyceridemia, ERN/LPRT therapy reduces the atherogenicity of postprandial triglyceride-rich particles and their remnants. Indeed, during exaggerated postprandial response, the vessel wall is more exposed to proatherogenic remnants which can penetrate into the subintimal space by transcytosis, in a receptor-independent mechanism. 26 TRL remnants are generated mainly by the action of lipoprotein lipase on chylomicrons and VLDL particles. 27 In close relationship with the impact of ERN/LRPT on postprandial plasma levels of both apoCII and apoCIII, it is likely that ERN/LRPT, thus, accelerates hydrolysis of TG-rich lipoproteins, mainly chylomicrons and large VLDL-1 particles. Indeed, we presently observed that ERN/LRPT therapy was associated with an increase in plasma levels of apoCII, whereas those of apoCIII were slightly reduced postprandially; such postprandial variations in apoCIII and apoCII levels being not observed before ERN/ LRPT treatment. ApoCII represents the most potent lipoprotein lipase activator, whereas apoCIII inhibits lipoprotein lipase activity 28 ; thus, the concomitant and opposite variations observed in apoCII and apoCIII after ER/LRPT therapy might favor intravascular catabolism of postprandial TRL particles. In addition, ERN/LRPT treatment abolished postprandial elevation in circulating levels of apoE, thus indicating a decrease in the generation of remnants particles. Taken together, those effects suggest that ERN/LRPT limits intravascular accumulation of TRL and their remnants and their further potential infiltration within the arterial wall.
We equally observed that ERN/LRPT abolished the postprandial elevation in endogenous CETP activity frequently observed in hyperlipidemic patients. Accelerated postprandial CETP-mediated CE transfer from HDL to TRL particles has been shown to favor the formation of CE-enriched remnants. 12 An enhanced CETP activity induces the concomitant formation of TG-enriched/CE-poor HDL particles which represent good substrate for hepatic lipase. 23 Such particles are thus rapidly transformed into smaller HDL particles, contributing to the reduction of circulating HDL-C levels and the establishment of a low HDL-C phenotype. We thus propose that the ERN/LPRT-induced limitation of postprandial CETPmediated CE transfer from HDL to TRL particles represents one mechanism by which niacin exerts its anti-atherogenic action, specifically by correcting the lipoprotein distribution toward an anti-atherogenic lipoprotein profile characterized by reduced plasma levels of TRL remnants and increased plasma levels of large HDL2 particles. This is in good agreement with in vivo studies showing that the effect of niacin on plasma HDL-C levels is intimately linked to CETP activity. 29 In addition, the lipoprotein distribution observed after ERN/ LPRT treatment display a high degree of homology with those observed after therapy with CETP inhibitors, suggesting a CETP inhibition-like effect of niacin. 30 We presently demonstrated that lipoprotein changes induced by ERN/LRPT treatment impact postprandial plasma cholesterol efflux capacity. Specifically, the capacity of postprandial plasma to stimulate cholesterol efflux via both ABCG1 and SR-BI was increased after ERN/LRPT treatment predominantly as a result of an increase in large HDL2 subspecies. These observations are in good agreement with previous studies showing an increase in plasma cholesterol efflux capacity from SR-BI and ABCG1 after niacin treatment in dyslipidemic patients. 31, 32 By contrast, we observed a decrease in the capacity of postprandial plasma to stimulate cholesterol efflux via ABCA1 after ERN/LRPT treatment. Pre-β-HDL particles represent the preferential acceptors of cholesterol via the ABCA1 pathway. These particles are generated in part by the dissociation of apoAI from HDL particles after the concomitant action of CETP and hepatic lipase. 33 We presently observed that ERN/LRPT reduces the activity of CETP, thereby potentially limiting the generation of pre-β-HDL. This observation is consistent with a previous study showing a reduction, even nonsignificant, in the capacity of serum to stimulate cholesterol efflux via ABCA1 after niacin treatment. 31 Finally, we observed that ERN/LRPT therapy slightly reduce postprandial plasma efflux capacity from human macrophages, indicating that the increase in cholesterol efflux via SR-BI and ABCG1 pathways failed to counterbalance the reduction in the ABCA1-dependent efflux. Earlier studies have demonstrated that the relative contribution of ABCA1 to human macrophage cholesterol efflux is predominant when compared with other specific pathways, mostly SR-BI, because ABCG1 has been shown to not contribute significantly to cholesterol efflux from human macrophage. 34, 35 In good agreement with earlier studies, we presently observed no impact of niacin treatment on a background of statin therapy on cholesterol efflux to apoB-depleted serum despite elevation in circulating HDL-C levels. 36 It is relevant to consider that in this latter study, efflux was evaluated using J774 mouse macrophage cells, thus reflecting an ABCA1-dependent efflux mechanism. Taken together, these observations highlight the contribution of apoB-containing lipoproteins in the SR-BI-dependent cholesterol efflux from human macrophages.
Using hApoB/hCETP transgenic mice as a humanized mouse model, we evaluated the turnover of postprandial HDL particles isolated from niacin-treated patients. Interestingly, we demonstrated that in patients receiving ERN/LRPT treatment, HDL particles generated during postprandial phase display an improved capacity to mediate selective hepatic uptake of CE to the liver. Even though nonsignificant, we presently observed a minor reduction in apoCIII levels after ERN/LRPT treatment. This variation in apoCIII levels occurred concomitantly with an increase in plasma apoCII levels. ApoCII and apoCIII represent activator and inhibitor of lipoprotein lipase, respectively, thus suggesting that intravascular catabolism of TRL particles is accelerated after ERN/LRPT treatment. After LDL-mediated TG hydrolysis, redundant lipids surface and apolipoproteins are then transferred from TRL particles to HDL, thus contributing to formation of larger HDL particles. Interestingly, these latter HDL particles have been previously shown to display a higher ability to interact with SR-BI for selective uptake of CE by the liver. 37 It is interesting to note that fasting HDL particles isolated from ERN/LRPT-treated patients displayed a reduced HDL-CE liver delivery as compared with their equivalent counterparts isolated from patients before ERN/LRPT treatment; however, an equivalent increase in HDL-mediated RCT to feces was observed, thus suggesting that niacin might increase cholesterol elimination via a liver-independent mechanism, such as the transintestinal cholesterol excretion pathway. 38 Human ApoB/CETP double transgenic mice fed with niacin showed significant reduction in P2Y13 gene expression in both the liver and intestine. The niacin-induced reduction in P2Y13 expression in the liver has been previously proposed as potential mechanism underlying HDL-C raising effect of niacin. 39 In addition, niacin induced an increase in the intestinal expression of ABCA1 gene, which might equally contribute to the elevation of circulating levels of HDL-C observed after niacin therapy. 40 In the enterocyte, ACAT2 catalyzes the esterification of free cholesterol, providing cholesterol oleate and palmitate assembly into the lipid core of chylomicrons and VLDL. 41 Its inhibition by niacin represents one potential mechanism for the reduction of apoB-containing lipoproteins assembly, leading to reduction of intestinal TRL particles synthesis during postprandial phase.
Two clinical trials, AIM-HIGH and HPS2-THRIVE, recently failed to demonstrate the benefit of adding niacin on a background of statin therapy to reduce cardiovascular outcomes. 5, 42 However, both trials involved patients who reached their LDL-C targets under aggressive lipid treatment, lowering considerably the chances to reveal a beneficial effect of niacin. A secondary analysis of the AIM-HIGH trial, performed in a subset of dyslipidemic patients displaying high TG (≥200 mg/dL) and low HDL-C levels (<32 mg/dL), demonstrated a significant reduction of cardiovascular risk in the ER niacin group (hazard ratio: 0.64; P=0.032). 43 In addition, nonfasting triglycerides are associated with incidence of cardiovascular events in particular in patients displaying a low HDL-C phenotype and elevated TG levels. 44 Thus, there may be a subgroup of patients who might still benefit from niacin treatment. Whether the subtle beneficial effects observed in our study translate into clinical benefit (reduction of events) and whether they are sufficient to overcome the high rate of side effects observed with niacin is unclear and should be tested in an appropriate outcome trial.
We presently demonstrated that addition of extended-release niacin/laropiprant to statin attenuates postprandial lipid response in dyslipidemic patients and induces a shift of the circulating lipoprotein profile toward an anti-atherogenic pattern. In addition, during postprandial phase, extended-release niacin/laropiprant therapy reduces CETP activity, moderately affects plasma efflux capacity from macrophages, increases the ability of HDL particles to deliver CE to the liver, and stimulates cholesterol elimination into feces. Taken together, these observations indicate that specific subgroups of patients at high cardiovascular risk might benefit from addition of niacin to their current statin treatment to improve their cardio protection. The role of niacin has been called into question by 2 recent outcome trials showing no benefit on cardiovascular events. Still, for certain high-risk patients having difficulty achieving their LDL-C target, niacin remains a significant therapeutic option.
Significance
